In the field of lymphoma, hematopathologists have played an important role in classifying and diagnosing lymphoma, as well as being responsible for treatment strategies. The pathological diagnosis should be made based on phenotypic, genotypic and morphological analysis. This concept is now also applied for other organ systems.
advances in bone marrow pathology for MDS, especially regarding this point.
In the MPN classification, following the discovery of driver genes beginning from CML, the importance of identifying specific genetic abnormalities was proposed as a "molecular first" in the 2008 classification. In the 2016 revision, in order to advance the understanding of primary myelofibrosis (PMF), prefibrotic/ early-stage PMF was proposed, in which early lesions, such as ET, are separated from other MPN. Bone marrow pathology was more reliable than cytology or molecular analysis for diagnosing these lesions. 4 "Pathology first" is the main issue for MPN classification. Dr. Fujiwara reviewed the overall pathological diagnosis process for MPN.
In the 2008 classification, refractory cytopenia of childhood (RCC) was added as a provisional entity of MDS. 5 The pediatric hematology field was confused by this category because pediatric MDS is very rare. As the presented clinical features were similar with those of aplastic anemia, there was doubt as to whether patients had aplastic anemia, methods to distinguish RCC, and whether there a diagnosis of RCC was clinically significant. In the registration system of the Japan Society of Pediatric Hematology, aplastic anemia and MDS were independent of each other, but in 2009, the review system was centralized for evaluating RCC. As a result, many cases of pediatric bone marrow failure were registered, and the central diagnosis revealed the existence of aplastic anemia and morphologically diagnosed RCC. 6 In addition, advances in genetic analysis have improved discrimination from congenital hematopoietic failure. Based on the central review results, Dr. Iwafuchi reviewed the pathology of pediatric bone marrow failure, including RCC and RCMD.
Although it is a lymphoid neoplasm, plasma cell myeloma has been assessed by cytology because bone marrow is the main proliferation site. Therefore, it is difficult to consider the concept of MGUS as lymphoma. Dr. Fujino reevaluated myeloma by bone marrow pathology, and provided a review based on morphology, phenotype, and genes involved.
All reviews reflected the recent progress of bone marrow pathology, and are expected to guide the field of hematopathology in the future.
